Formation markers: bone‑specific ALP, osteocalcin, P1NP. Resorption markers: CTX (C‑telopeptide), NTX, TRAP‑5b. Uses: monitoring therapy in osteoporosis and metabolic bone disease, not for diagnosis alone. Preanalytic variability: diurnal variation (fasting morning samples), renal/hepatic function influences.
Which of the following is a bone formation marker that specifically reflects osteoblastic activity?
What is the primary clinical use of bone turnover markers in osteoporosis management?
Which of the following markers is classified as a bone resorption marker?
Which factor can lead to preanalytic variability in the measurement of bone turnover markers?
What is the significance of measuring osteocalcin in a clinical setting?
In which condition would you expect elevated levels of N-terminal telopeptide?
Which of the following markers is NOT typically used as a bone turnover marker?
What is the role of TRAP-5b in bone metabolism?
Why is it important to assess renal and hepatic function when interpreting bone turnover markers?
Which of the following statements is true regarding the use of bone turnover markers?
